William J. Rhead, MD, PhD
Pediatric geneticist, Children's Hospital of Wisconsin; professor, Pediatrics and Pathology, Medical College of Wisconsin
Human fatty acid oxidation disease, mitochondrial disease, newborn screening.
Medical degree, University of California, San Diego, 1974; doctorate, University of California, San Diego, 1974; residency, North Carolina Memorial Hospital, Chapel Hill, 1977; fellowships, Research, University of California, San Diego, 1975, and Human Genetics and Pediatrics, Yale University School of Medicine, New Haven, Conn. 1979.
Pediatrics, Human Genetics (Clinical Genetics and Clinical Biochemical Genetics).
Noel Raine Prize, Society for the Study of Inborn Errors of Metabolism, 1983; Best Doctors in America, 1992, 1994, 1998, 2003.
Meet Dr. Rhead and learn about the Genetics Center at Children's Hospital of Wisconsin by watching the following video:
- Brix AE, Elgavish A, Nagy TR, Gower BA, Rhead WJ, Wood PA. Evaluation of Liver Fatty Acid Oxidation in the Leptin Deficient Obese Mouse. Molecular Genetics and Metabolism. 2002; 75(3):219-226.
- Koch R, Burton B, Hoganson G, Peterson R, Rhead W, Rouse B, Scott R, Wolff J, Guttler F, Nelson M, de la Cruz F, Coldwell J, Erbe R, Geraghty MT, Shear C, Thomas J, Azen C. Phenylketonuria in Adulthood: A Collaborative Study. Journal of Inheritated Metabolic Disease. 2002; 25(5):333-346.
- Brix AE, Elgavish A, Nagy TR, Gower BA, Rhead WJ, Wood PA. Evaluation of Fatty Acid Oxidation in the Leptin Deficient Obese Mouse. Molecular Genetics and Metabolism. 2002; 75:219-26.
- Cox KM, Hamm DA, Millington DS, Matern D, Vockley J, Rinaldo R, Pinkert CA, Rhead WJ, Lindsey R, Wood PA. Gestational, Pathologic and Biochemical Differences between very Long-chain Acyl-CoA Dehydrogenase Deficiency and Long-chain Acyl-CoA Dehydrogenase Deficiency in the Mouse. Human Molecular Genetics. 2001; 10(19) 2069-76.
- Koch R, Burton B, Hoganson G, Peterson R, Rhead W, Rouse B, Scott R, Wolff J, Stern AM, Guttler F, Neslon M, DeLaCruz F, Coldwell J, Erbe R, Geraghty MT, Shear C, Thomas J, Azen C. Phenylketonuria in Adulthood: A Collaborative Study. Journal of Inherited Metabolic Diseases. 2002; 25:333-346.
- Rhead WJ. Introduction to Symposium, Washington D.C., on Mitochondrial Myopathies and Disorders of the Electron Transport Chain in Man: A Molecular and Clinical Update. Pediatric Research. 1990; 28:524.
- Roettger V, Marshall T, Amendt B, Rhead WJ. Multiple Acyl-Coenzyme A Dehydrogenase Disorder (MAD) Responsive to Riboflavin: Biochemical Studies in Fibroblasts. In New Developments in Fatty Acid Oxidation, Paul Coates and Kay Tanaka, eds. 1992; 375:317-326.
- Gordon JA, Heller SK, Rhead WJ, Watkins PA, Spector AA. Formation of a Novel Arachidonic Acid Metabolite in Peroxisomes. Prostaglandins, Leukotrienes and Essential Fatty Acids. 1995; 52:77-81.
- Rhead WJ. Inborn Errors of Metabolism in Present Knowledge. In Nutrition, Ziegler and Filer, eds., seventh edition. ILSI Press, Washington, D.C., 1996; 623-629.
- Lysaught MT, Milhollin L, Peirce R, Getchell J, Rhead W, Susanin J, Anderson J, Murray JC. A Pilot Test of DNA-based Analysis Using Anonymized Newborn Screening Cards. In Iowa, Stored Tissue Samples: Ethical Legal, and Public Policy Implications. R.F. Weir, ed., University of Iowa Press, Iowa City, 1998; 3-31.
- Rhead WJ, Irons M. The Call from the Newborn Screening Laboratory: Frustration in the Afternoon. Pediatric Clinics of North America. 2004.
- A Phase 3, Open-label Study of the Safety of HPN-100 for the Long-term Treatment of Urea Cycle Disorders, Hyperion Therapeutics, Inc., principal investigator.
- An Open-label Treatment Protocol to Evaluate the Safety of Replagal Treatment in Patients with Fabry Disease, Shire Human Genetic Therapies, principal investigator.
- Long Term Use of HPN-100 in Urea Cycle Disorders, Hyperion Therapeutics, Inc., principal investigator.
- Region 4 Genetics Collaborative Grant, University of Michigan, Michigan Public Health, principal investigator.
- Congentical Disorders Progra, State of Wisconsin, principal investigator.
- Gaucher Disease Outcomes Survey, Shire Human Genetic Therapies, principal investigator.
- A Randomized, Open-Label Study to Compare the Efficacy and Safety of AT1001 and Enzyme Replacement Therapy (ERT) in Patients with Fabry Disease and AT1001-Responsive GLA Mutations, Who Were Previously Treated with ERT, Amicus Therapeutics, principal investigator.
Children's Research Institute
8701 Watertown Plank Road
Wauwatosa, WI 53226
Phone: (414) 266-2979
Fax: (414) 266-1616
Investigator in the areas of: